Industry executives can share their views on the “national priority” program at a June meeting. Elsewhere, Sanofi licensed a ...
The hefty funding will support a U.S. and China-based startup that’s amassed a pipeline of nearly 20 drugs and formed two ...
In a letter to European patients, Roche said its decision to end development of “emugrobart” was based on the drug “not ...
Acquiring a unit of privately held Synnovation Therapeutics hands Novartis a prospect that might improve on medicines that, like its own Piqray, target tumors driven to growth by PIK3CA mutations.
Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...
The clearance, issued 54 days after an approval submission, gives Novo another chance to claw back market share from Eli ...
Retatrutide, a possible advance on GLP-1 drugs like Zepbound, significantly cut blood sugar and body weight in the study, a ...
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...
After a lengthy downturn, renewed optimism is building among young drugmakers and their backers as a new funding wave takes ...
The planned Shanghai facility extends a yearslong push into the field and will support CAR-T therapies AstraZeneca is making ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results